D95. Challenges and Advances in Covid-19 2023
DOI: 10.1164/ajrccm-conference.2023.207.1_meetingabstracts.a6576
|View full text |Cite
|
Sign up to set email alerts
|

Cova Results From a Double-blind, Placebo-controlled Phase 2/3 Study to Assess Efficacy and Safety of BIO101 in Hospitalized Severe COVID-19 Patients

Help me understand this report

This publication either has no citations yet, or we are still processing them

Set email alert for when this publication receives citations?

See others like this or search for similar articles